Clinical Trial Update: A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC] [Phase 1]

View source ↗

Summary

The Phase 1 study of Debio 0932 in combination with standard of care for non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Debio-0932 (Debio-0932)

Snippet

Sponsor: Debiopharm International SA | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: TERMINATED